

Patient Reported Outcomes in Breast Cancer

1. Basch E, Bennett A, Pietanza MC. Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. *J Natl Cancer Inst.* 2011;103(24):1808-10.
2. Marzban S, Shokravi S, Abaei S, Fattahi P, Karami M, Tajari F. Patient-Reported Outcome Measures of Breast Cancer Surgery: Evidence Review and Tool Adaptation. *Cureus.* 2022;14(8):e27800.
3. Tevis SE, James TA, Kuerer HM, Pusic AL, Yao KA, Merlino J, et al. Patient-Reported Outcomes for Breast Cancer. *Ann Surg Oncol.* 2018;25(10):2839-45.
4. Chen CM, Cano SJ, Klassen AF, King T, McCarthy C, Cordeiro PG, et al. Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. *Breast J.* 2010;16(6):587-97.
5. Efficace F, Fayers P, Pusic A, Cemal Y, Yanagawa J, Jacobs M, et al. Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials. *Cancer.* 2015;121(18):3335-42.
6. Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. *Ann Oncol.* 2015;26(9):1846-58.
7. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. *Plast Reconstr Surg.* 2009;124(2):345-53.
8. Badaoui S, Kichenadasse G, Rowland A, Sorich MJ, Hopkins AM. Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib. *Oncologist.* 2021;26(7):562-8.
9. Modi ND, Danell NO, Perry RNA, Abuhelwa AY, Rathod A, Badaoui S, et al. Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer. *ESMO Open.* 2022;7(3):100475.
10. Efficace F, Rees J, Fayers P, Pusic A, Taphoorn M, Greimel E, et al. Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry. *Health Qual Life Outcomes.* 2014;12:86.
11. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA.* 2013;309(8):814-22.

Management of Colorectal Liver Metastases

1. Lee HY, Woo IS. Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. *Cancers (Basel)*. Sep 13 2021;13(18)doi:10.3390/cancers13184590
2. Famularo S, Milana F, Cimino M, et al. Upfront Surgery versus Neoadjuvant Perioperative Chemotherapy for Resectable Colorectal Liver Metastases: A Machine-Learning Decision Tree to Identify the Best Potential Candidates under a Parenchyma-Sparing Policy. *Cancers (Basel)*. Jan 18 2023;15(3)doi:10.3390/cancers15030613
3. Morine Y, Ikemoto T, Iwahashi S, et al. Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis. *Anticancer Res*. Sep 2019;39(9):5089-5096. doi:10.21873/anticancer.13703
4. Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? *Br J Cancer*. May 2023;128(10):1797-1806. doi:10.1038/s41416-023-02213-1
5. Mimmo A, Pegoraro F, Rhaïem R, et al. Microwave Ablation for Colorectal Liver Metastases: A Systematic Review and Pooled Oncological Analyses. *Cancers (Basel)*. Mar 03 2022;14(5)doi:10.3390/cancers14051305
6. Chan G, Chee CE. Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer. *Cancers (Basel)*. Nov 26 2020;12(12)doi:10.3390/cancers12123535
7. Yu X, Zhu L, Liu J, Xie M, Chen J, Li J. Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis. *Onco Targets Ther*. 2020;13:11645-11658. doi:10.2147/OTT.S271955
8. Sanuki N, Takeda A, Tsurugai Y, Eriguchi T. Role of stereotactic body radiotherapy in multidisciplinary management of liver metastases in patients with colorectal cancer. *Jpn J Radiol*. Oct 2022;40(10):1009-1016. doi:10.1007/s11604-022-01307-9

Criteria for Adjuvant Therapy for Stage II Melanoma

1. Eggermont AMM, Spatz A, Robert C. Cutaneous melanoma. *Lancet*. 2014;383:816-827.
2. Canadian Cancer Society. Melanoma: deadliest type of skin cancer is on the rise [news release]. Ottawa: Canadian Cancer Society; 28 May 2014. Available: www.cancer.ca/en/about-us/for-media/mediareleases/national/2014/2014-canadian-cancer-statistics/?region=on
3. (accessed 2019 Nov. 9).
4. Poklepovic AS, Luke JJ. Considering adjuvant therapy for stage II melanoma. *Cancer*. 2020;126(6):1166-1174.
5. Yushak M, Mehnert J, Luke J, Poklepovic A. Approaches to High-Risk Resected Stage II and III Melanoma. *Am Soc Clin Oncol Educ B*. 2019;(39):e207-e211.
6. Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. *Ann Surg Oncol*. 2018;25(8):2105-2110.
7. Bartlett EK, Karakousis GC. Current staging and prognostic factors in melanoma. *Surg Oncol Clin N Am*. 2015;24(2):215-227.

8. Lee R, Mandala M, Long G V., et al. Adjuvant therapy for stage II melanoma: the need for further studies. *Eur J Cancer*. 2023;189:112914.
9. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *N Engl J Med*. 2017;377(19):1824-1835.
10. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *N Engl J Med*. 2018;378(19):1789-1801.
11. Long G V., Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. *N Engl J Med*. 2017;377(19):1813-1823.
12. Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. *Lancet*. 2022;399(10336):1718-1729.
13. Long GV, Del Vecchio M, Weber, J, et al. Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K). *SKIN The Journal of Cutaneous Medicine*, 2023;7(2), s163. <https://doi.org/10.25251/skin.7.suppl.163>

Mismatch Repair Testing in Gastrointestinal Cancers: An Essential Insight

1. Bartley AN, Mills AM, Konnick E, Overman M, Ventura CB, Souter L, et al. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline from the College of American Pathologists in Collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer. *Arch Pathol Lab Med*. 2022 Oct 1;146(10):1194–210.
2. Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, et al. Microsatellite Instability Is Associated with the Presence of Lynch Syndrome Pan-Cancer. *Journal of Clinical Oncology* [Internet]. 2018 Oct 30 [cited 2023 Aug 12]; Available from: <https://ascopubs.org/doi/10.1200/JCO.18.00283>
3. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *The Journal of Molecular Diagnostics: JMD*. 2017 Mar;19(2):187.
4. Dt L, Jn D, Kn S, H W, Br B, Lk A, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science (New York, NY)* [Internet]. 2017 Jul 28 [cited 2023 Aug 13];357(6349). Available from: <https://pubmed.ncbi.nlm.nih.gov/28596308/>
5. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med*. 2015 Jun 25;372(26):2509–20.
6. Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. *Journal for Immunotherapy of Cancer* [Internet]. 2018 [cited 2023 Aug 13];6. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950135/>
7. K P, L M, D M, R DL, G R, V S, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. *The British journal of*

surgery [Internet]. 2018 Feb [cited 2023 Aug 13];105(3). Available from: <https://pubmed.ncbi.nlm.nih.gov/29091259/>

8. Vos EL, Maron SB, Krell RW, Nakauchi M, Fiasconaro M, Walch HS, et al. The interaction between microsatellite instability high (MSI-high) gastric cancer and chemotherapy on survival. *Journal of Clinical Oncology* [Internet]. 2021 Jan 22 [cited 2023 Aug 14]; Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.244
9. Do H, Wd B, Mr W, Yn Y, Jf R, D F, et al. Clinical Practice Guidelines for the Surgical Treatment of Patients with Lynch Syndrome. *Diseases of the colon and rectum* [Internet]. 2017 Feb [cited 2023 Aug 14];60(2). Available from: <https://pubmed.ncbi.nlm.nih.gov/28059909/>
10. Cavestro GM, Mannucci A, Balaguer F, Hampel H, Kupfer SS, Repici A, et al. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines. *Clinical Gastroenterology and Hepatology*. 2023 Mar 1;21(3):581-603.e33.
11. R C, J T, J F, G Y, R G, T Y, et al. Microsatellite Instability in Patients with Stage III Colon Cancer Receiving Fluoropyrimidine with or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* [Internet]. 2021 Feb 20 [cited 2023 Aug 12];39(6). Available from: <https://pubmed.ncbi.nlm.nih.gov/33356421/>
12. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J Clin Oncol*. 2010 Jul 10;28(20):3219–26.
13. A R, M F, G L. Immunohistochemical evaluation of mismatch repair proteins in colorectal carcinoma: the AIFEG/GIPAD proposal. *Pathologica* [Internet]. 2016 Sep [cited 2023 Aug 14];108(3). Available from: <https://pubmed.ncbi.nlm.nih.gov/28195261/>
14. C G, M C, L O, E D. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. *European journal of cancer (Oxford, England: 1990)* [Internet]. 2010 Oct [cited 2023 Aug 12];46(15). Available from: <https://pubmed.ncbi.nlm.nih.gov/20627535/>
15. Merck.com [Internet]. [cited 2023 Aug 12]. FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients with Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors. Available from: <https://www.merck.com/news/fda-converts-to-full-approval-indication-for-keytruda-pembrolizumab-for-certain-adult-and-pediatric-patients-with-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient/>
16. Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. *JCO Precision Oncology* [Internet]. 2017 Oct 3 [cited 2023 Aug 10]; Available from: <https://ascopubs.org/doi/10.1200/PO.17.00073>

PRRT for Small Bowel Neuroendocrine Tumors

1. Van der Zwan WA, Bodei L, MuellerBrand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: radionuclide therapy in neuroendocrine tumors. *Eur J Endocrinol* 2015;172:R1-8.
2. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol* 2008;26:2124-30.
3. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. *N Engl J Med*. 2017;376(2):125-135.
4. Strosberg JR, Al-Toubah T, Pellè E, et al. Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. *J Nucl Med*. 2021;62(1):69-72
5. CNETS: Peptide Receptor Radionuclide Therapy. <https://cnets.ca/patients-caregivers/net-diagnosis-and-treatments/net-treatments/prrt/>
6. BCCA: Neuroendocrine Tumours. Revised November 2018. <http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-management-manual/gastrointestinal/neuroendocrine-tumours#Non-Pancreatic-Neuroendocrine-Tumors>
7. BCCA: Chemotherapy protocols – UGIPRRT. Revised April 2023. http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Gastrointestinal/UGIPRRT_Protocol.pdf
8. Levart D, Kalogianni E, Corcoran B, Mulholland N, Vivian G. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. *EJNMMI Phys*. 2019 Apr 25;6(1):7.
9. Hendifar AE, Mehr SH, McHaffie DR. Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. *Pancreas*. 2022 Mar 1;51(3):213-218